Form 8-K
8-K — CARDINAL HEALTH INC
Accession: 0000721371-26-000017
Filed: 2026-04-30
Period: 2026-04-30
CIK: 0000721371
SIC: 5122 (WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES)
Item: Results of Operations and Financial Condition
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — cah-20260430.htm (Primary)
EX-99.1 (a26q3_x033126xex991xnewsre.htm)
GRAPHIC (essentialtocarea55.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: cah-20260430.htm · Sequence: 1
cah-20260430
0000721371false00007213712026-04-302026-04-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2026
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
Ohio 1-11373 31-0958666
(State or other
jurisdiction of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
7000 Cardinal Place, Dublin, Ohio 43017
(614) 757-5000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common shares (without par value) CAH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. p
Item 2.02: Results of Operations and Financial Condition
On April 30, 2026, Cardinal Health, Inc. (the "Company") issued a news release announcing its results for the quarter ended March 31, 2026. A copy of the news release is included as Exhibit 99.1 to this report.
Item 7.01: Regulation FD Disclosure
During a webcast scheduled to be held at 8:30 a.m. Eastern time on April 30, 2026, the Company's Chief Executive Officer and Chief Financial Officer will discuss the Company's results for the quarter ended March 31, 2026 and outlook for the fiscal year ending June 30, 2026. The slide presentation for the webcast will be available on the Investors page at ir.cardinalhealth.com. An audio replay of the webcast also will be available on the Investors page at ir.cardinalhealth.com.
Item 9.01: Financial Statements and Exhibits
(d) Exhibits
Exhibit
Number Exhibit Description
99.1
News release issued by the Company on April 30, 2026 announcing third-quarter results.
2
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cardinal Health, Inc.
(Registrant)
Date: April 30, 2026 By: /s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer
3
EX-99.1
EX-99.1
Filename: a26q3_x033126xex991xnewsre.htm · Sequence: 2
Document
Exhibit 99.1
FOR IMMEDIATE RELEASE
Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook
•Revenue increased 11% to $60.9 billion
•GAAP1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69
•Non-GAAP operating earnings increased 18% to $956 million; non-GAAP diluted EPS increased 35% to $3.17
•Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance2 to $10.70 to $10.80
•Cardinal Health reduces debt and completes additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billion
DUBLIN, Ohio, April 30, 2026 – Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025.
Third quarter GAAP operating earnings decreased 30% to $509 million and GAAP diluted earnings per share (EPS) decreased 20% to $1.69, reflecting a $184 million pre-tax goodwill impairment in the company's Navista & ION reporting unit primarily due to changes in the risk profile of the business plans resulting in an increase in the discount rate. These changes reflect business model updates and base operational performance.
Third quarter non-GAAP operating earnings increased 18% to $956 million. Non-GAAP diluted EPS increased 35% to $3.17, reflecting the increase in non-GAAP operating earnings, a lower non-GAAP effective tax rate and a lower share count, partially offset by an increase in interest and other expense.
“An excellent third quarter extends our FY26 momentum, due to the durability and resilience of our business,” said Jason Hollar, CEO of Cardinal Health. “We were pleased to see strong operating performance led by Pharmaceutical and Specialty Solutions and our three growth businesses, positioning us for long-term value creation and giving us the confidence to again raise our fiscal 2026 outlook.”
Q3 FY26 summary
Q3 FY26 Q3 FY25 Y/Y
Revenue $60.9 billion $54.9 billion 11%
Operating earnings $509 million $730 million (30)%
Non-GAAP operating earnings $956 million $807 million 18%
Net earnings attributable to Cardinal Health, Inc. $399 million $506 million (21)%
Non-GAAP net earnings attributable to Cardinal Health, Inc. $750 million $568 million 32%
Effective Tax Rate3
3.1% 23.6%
Non-GAAP Effective Tax Rate3
10.2% 22.4%
Diluted EPS attributable to Cardinal Health, Inc. $1.69 $2.10 (20)%
Non-GAAP diluted EPS attributable to Cardinal Health, Inc. $3.17 $2.35 35%
Cardinal Health
Page 2
Segment results
Pharmaceutical and Specialty Solutions segment
Q3 FY26 Q3 FY25 Y/Y
Revenue $ 56.1 billion $ 50.4 billion 11%
Segment profit $ 784 million $ 662 million 18%
Third quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 11% to $56.1 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
Pharmaceutical and Specialty Solutions segment profit increased 18% to $784 million in the third quarter, driven by contributions from brand and specialty products and positive generics program performance.
Global Medical Products and Distribution segment
Q3 FY26 Q3 FY25 Y/Y
Revenue $ 3.1 billion $ 3.2 billion —%
Segment profit
$ 25 million $ 39 million (36)%
Third quarter revenue for the Global Medical Products and Distribution segment was generally flat to the prior year. This reflected lower distribution volumes, offset by Cardinal Health brand growth.
Global Medical Products and Distribution segment profit decreased 36% to $25 million in the third quarter, primarily due to the adverse net impact of tariffs.
Other4
Q3 FY26 Q3 FY25 Y/Y
Revenue $ 1.7 billion $ 1.3 billion 31%
Segment profit
$ 179 million $ 134 million 34%
Third quarter revenue for Other increased 31% to $1.7 billion, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), Nuclear and Precision Health Solutions and OptiFreight Logistics.
Other segment profit increased 34% to $179 million in the third quarter, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), OptiFreight Logistics and Nuclear and Precision Health Solutions.
Cardinal Health
Page 3
Fiscal year 2026 outlook2
Cardinal Health is raising and narrowing its fiscal year 2026 guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $10.70 to $10.80 (+30% to +31% growth). This updated guidance reflects:
Improved operating segment performance:
•Pharmaceutical and Specialty Solutions segment profit growth of 22% to 23%, from the prior range of 20% to 22%
•Other segment profit growth of 36% to 38%, from the prior range of 33% to 35%
Net below-the-line improvements:
•Non-GAAP effective tax rate decreased to approximately 19%, from the prior range of 21% to 23%
•Diluted weighted average shares outstanding decreased to approximately 237 million, from the prior outlook of 237 million to 238 million
•Interest and Other expense updated to approximately $340 million, from the prior guidance of approximately $325 million
Improved free cash flow:
•Adjusted free cash flow raised and narrowed to $3.3 billion to $3.7 billion, from prior guidance of $3.0 billion to $3.5 billion
Recent highlights
•Cardinal Health announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at its Nuclear and Precision Health Solutions Center for Theranostics Advancement (CTA) in Indianapolis, Indiana, substantially increasing supply for use in investigational therapeutic drug products and future commercial manufacturing novel therapies.
•Specialty Networks and The Specialty Alliance entered an arrangement to partner in supporting a pharma company on a multi-year study focused on understanding real world outcomes. Patients will receive care at community gastroenterology clinics across the country with Specialty Networks performing the analysis of the results.
•Cardinal Health reduced debt, completing $100M term loan payment ahead of schedule and lowered its leverage ratio5 to 3.0X, maintaining its targeted range of 2.75 - 3.25X and its investment grade rating.
•Cardinal Health recently completed an additional $250 million accelerated share repurchase program, bringing year-to-date share repurchases in fiscal year 2026 to $1.0 billion.
Cardinal Health
Page 4
Webcast
Cardinal Health will host a webcast today at 8:30 a.m. ET to discuss third quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required.
Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company’s customer-centric focus drives continuous improvement and leads to innovative solutions that improve people’s lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.
Contacts
Media: Erich Timmerman, Erich.Timmerman@cardinalhealth.com and 614.757.8231
Investors: Matt Sims, Matt.Sims@cardinalhealth.com and 614.553.3661
1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.
2The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.
3The company achieved a GAAP effective tax rate of 3.1% and non-GAAP effective tax rate of 10.2% during the third quarter primarily as a result of discrete planning benefits.
4Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight Logistics, which are not significant enough individually to require reportable segment disclosure.
5The company maintains a targeted leverage range of 2.75x to 3.25x Adjusted Debt to EBITDA as defined by Moody’s Ratings. The company achieved 3.0x leverage as of March 31, 2026 per internal estimates.
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website.
Cardinal Health
Page 5
Cautions Concerning Forward-Looking Statements
This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," “will," "should," "could," "would," "project," "continue,” "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include our ability to manage uncertainties associated with the pricing of branded pharmaceuticals including those arising from proposed or final regulatory changes, the risk that we may fail to achieve our strategic objectives, including the operation of recently acquired entities and the continued execution of the GMPD Improvement Plan initiatives; risks and uncertainties related to tariffs, including the risk that we may not be able to offset increased costs or that we will lose customers if our competitors do not increase price on impacted products to the same extent that we do, competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts, whether due to price increases or otherwise; risks associated with litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act; the risk that events outside of our control, such as weather or geopolitical events, including the recent conflict with Iran, may impact costs for our products or may cause supply delays or shortages or manufacturing delays that impact our cost and ability to fulfill customer demand; and the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8K reports and exhibits to those reports. This release reflects management’s views as of April 30, 2026. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed. Cardinal Health provides definitions and reconciliations of non-GAAP financial measures and their most directly comparable GAAP financial measures at ir.cardinalhealth.com
Schedule 1
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (Unaudited)
Third Quarter
Year-to-Date
(in millions, except per common share amounts) 2026 2025 % Change 2026 2025 % Change
Revenue $ 60,940 $ 54,878 11 % $ 190,576 $ 162,419 17 %
Cost of products sold 58,442 52,755 11 % 183,362 156,453 17 %
Gross margin 2,498 2,123 18 % 7,214 5,966 21 %
Operating expenses:
Distribution, selling, general and administrative expenses 1,542 1,315 17 % 4,507 3,898 16 %
Restructuring and employee severance 25 28 66 61
Amortization and other acquisition-related costs 114 152 348 331
Acquisition-related cash and share-based compensation costs 112 20 243 20
Impairments and (gain)/loss on disposal of assets, net
185 (17) 173 (15)
Litigation (recoveries)/charges, net 11 (105) (7) (176)
Operating earnings 509 730 (30) % 1,884 1,847 2 %
Other (income)/expense, net 16 (9) (5) (11)
Interest expense, net 101 74 36 % 269 141 91 %
Earnings before income taxes 392 665 (41) % 1,620 1,717 (6) %
Provision for income taxes
12 157 (92) % 315 391 (19) %
Net earnings 380 508 (25) % 1,305 1,326 (2) %
Less: Net (earnings)/loss attributable to noncontrolling interests
19 (2) 11 (4)
Net earnings attributable to Cardinal Health, Inc. $ 399 $ 506 (21) % $ 1,316 $ 1,322 — %
Earnings per common share attributable to Cardinal Health, Inc.:
Basic $ 1.69 $ 2.11 (20) % $ 5.56 $ 5.47 2 %
Diluted 1.69 2.10 (20) % 5.54 5.44 2 %
Weighted-average number of common shares outstanding:
Basic 235 240 237 242
Diluted 236 241 238 243
Schedule 2
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions) March 31, 2026 June 30, 2025
Assets (Unaudited)
Current assets:
Cash and equivalents $ 3,937 $ 3,874
Trade receivables, net 13,648 13,242
Inventories, net 18,007 16,831
Prepaid expenses and other 2,472 2,414
Assets held for sale — 12
Total current assets 38,064 36,373
Property and equipment, net 2,928 2,858
Goodwill and other intangibles, net 13,698 12,177
Other assets 1,999 1,714
Total assets $ 56,689 $ 53,122
Liabilities and Shareholders’ Deficit
Current liabilities:
Accounts payable $ 37,834 $ 34,713
Current portion of long-term obligations and other short-term borrowings 671 550
Other accrued liabilities 3,484 3,634
Total current liabilities 41,989 38,897
Long-term obligations, less current portion 8,245 7,977
Deferred income taxes and other liabilities 9,127 8,882
Total shareholders’ deficit (2,672) (2,634)
Total liabilities and shareholders’ deficit $ 56,689 $ 53,122
Schedule 3
Cardinal Health, Inc. and Subsidiaries
Consolidated Statements of Cash Flows (Unaudited)
Third Quarter Year-to-Date
(in millions) 2026 2025 2026 2025
Cash flows from operating activities:
Net earnings $ 380 $ 508 $ 1,305 $ 1,326
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization 248 207 715 581
Impairments and loss on sale of other investments 15 — 20 2
Impairments and (gain)/loss on disposal of assets, net 185 (17) 173 (15)
Share-based compensation 129 31 309 91
Provision for bad debts 20 13 47 41
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables (17) (114) (215) (367)
(Increase)/decrease in inventories 2,094 758 (1,185) (1,209)
Increase/(decrease) in accounts payable (1,163) 1,424 3,013 954
Repurchases of liability-classified Specialty Alliance Units
(5) — (27) —
Other accrued liabilities and operating items, net (63) 114 (673) (527)
Net cash provided by operating activities 1,823 2,924 3,482 877
Cash flows from investing activities:
Acquisition of subsidiaries, net of cash acquired (42) (2,779) (1,967) (3,855)
Additions to property and equipment (146) (126) (385) (315)
Proceeds from the disposal of property and equipment — 3 31 3
Proceeds from investments 27 5 27 7
Proceeds from short-term investment in time deposit — — — 200
Other investing items, net
(20) (2) (9) (2)
Net cash used in investing activities (181) (2,898) (2,303) (3,962)
Cash flows from financing activities:
Proceeds from long-term obligations, net of issuance costs 2 — 991 2,869
Reduction of long-term obligations (113) (11) (637) (434)
Payments to noncontrolling interests, net (4) (7) (8) (7)
Net tax proceeds/(withholding) from share-based compensation 2 3 (79) (12)
Dividends on common shares (120) (124) (371) (374)
Purchase of treasury shares, net (250) (375) (1,008) (765)
Net cash provided by/(used in) financing activities (483) (514) (1,112) 1,277
Effect of exchange rate changes on cash and equivalents 1 4 (4) 1
Net increase/(decrease) in cash and equivalents
1,160 (484) 63 (1,807)
Cash and equivalents at beginning of period 2,777 3,810 3,874 5,133
Cash and equivalents at end of period $ 3,937 $ 3,326 $ 3,937 $ 3,326
Schedule 4
Cardinal Health, Inc. and Subsidiaries
Segment Information
Third Quarter
Pharmaceutical and Specialty Solutions Global Medical Products and Distribution Other
(in millions) 2026 2025 2026 2025 2026 2025
Revenue
Amount $ 56,111 $ 50,433 $ 3,148 $ 3,160 $ 1,706 $ 1,304
Growth rate 11 % — % — % 2 % 31 % 13 %
Segment profit
Amount $ 784 $ 662 $ 25 $ 39 $ 179 $ 134
Growth rate 18 % 14 % (36) % 77 % 34 % 22 %
Segment profit margin 1.40 % 1.31 % 0.79 % 1.23 % 10.49 % 10.28 %
Year-to-Date
Pharmaceutical and Specialty Solutions Global Medical Products and Distribution Other
(in millions) 2026 2025 2026 2025 2026 2025
Revenue
Amount $ 175,985 $ 149,272 $ 9,591 $ 9,437 $ 5,071 $ 3,773
Growth rate 18 % (3) % 2 % 2 % 34 % 13 %
Segment profit
Amount $ 2,138 $ 1,723 $ 108 $ 65 $ 524 $ 356
Growth rate 24 % 12 % 66 % 44 % 47 % 14 %
Segment profit margin 1.21 % 1.15 % 1.13 % 0.69 % 10.33 % 9.44 %
The sum of the components and certain computations may reflect rounding adjustments.
Schedule 5
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1
Net
(Earnings)/Loss
Gross Operating Earnings Provision Attributable Net Diluted
Margin
SG&A2
Earnings Before for to Non-
Earnings3
Effective
EPS 3
(in millions, except per common share amounts) Gross Growth Growth Operating Growth Income Income controlling Net Growth Tax Diluted Growth
Margin Rate
SG&A2
Rate Earnings Rate Taxes Taxes Interests
Earnings3
Rate Rate
EPS 3
Rate
Third Quarter 2026
GAAP $ 2,498 18 % $ 1,542 17 % $ 509 (30) % $ 392 $ 12 $ 19 $ 399 (21) % 3.1 % $ 1.69 (20) %
Restructuring and employee severance — — 25 25 6 — 19 0.08
Amortization and other acquisition-related costs — — 114 114 43 — 71 0.30
Acquisition-related cash & share-based compensation costs — — 112 112 4 — 108 0.46
Impairments and (gain)/loss on disposal of assets, net 4
— — 185 185 22 (23) 140 0.59
Litigation (recoveries)/charges, net — — 11 11 (2) — 13 0.06
Non-GAAP $ 2,498 18 % $ 1,542 17 % $ 956 18 % $ 840 $ 86 $ (4) $ 750 32 % 10.2 % $ 3.17 35 %
Third Quarter 2025
GAAP $ 2,123 10 % $ 1,315 4 % $ 730 98 % $ 665 $ 157 $ (2) $ 506 94 % 23.6 % $ 2.10 96 %
Restructuring and employee severance — — 28 28 7 — 21 0.09
Amortization and other acquisition-related costs — — 152 152 34 (2) 116 0.48
Acquisition-related cash & share-based compensation costs — — 20 20 1 (4) 15 0.06
Impairments and (gain)/loss on disposal of assets, net — — (17) (17) (4) — (13) (0.06)
Litigation (recoveries)/charges, net — — (105) (105) (27) — (78) (0.32)
Non-GAAP $ 2,122 10 % $ 1,315 4 % $ 807 21 % $ 741 $ 166 $ (7) $ 568 11 % 22.4 % $ 2.35 13 %
1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.
2 Distribution, selling, general and administrative expenses.
3 Attributable to Cardinal Health, Inc.
4 For the three months ended March 31, 2026, impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $184 million related to the Navista & ION reporting unit within the Pharma segment. For fiscal 2026, the estimated net tax benefit related to the impairments is $23 million and is included in the annual effective tax rate. The portion of the goodwill impairment charge attributable to noncontrolling interests is $23 million.
The sum of the components and certain computations may reflect rounding adjustments.
We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.
Schedule 5
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1
Net
(Earnings)/Loss
Gross Operating Earnings Provision Attributable Net Diluted
Margin
SG&A2
Earnings Before for to Non-
Earnings3
Effective
EPS 3
(in millions, except per common share amounts) Gross Growth Growth Operating Growth Income Income controlling Net Growth Tax Diluted Growth
Margin Rate
SG&A2
Rate Earnings Rate Taxes Taxes Interests
Earnings3
Rate Rate
EPS 3
Rate
Year-to-Date 2026
GAAP $ 7,214 21 % $ 4,507 16 % $ 1,884 2 % $ 1,620 $ 315 $ 11 $ 1,316 — % 19.4 % $ 5.54 2 %
State opioid assessments related to prior fiscal years — 17 (17) (17) (4) — (13) (0.05)
Restructuring and employee severance — — 66 66 15 — 51 0.21
Amortization and other acquisition-related costs — — 348 348 92 — 256 1.08
Acquisition-related cash & share-based compensation costs — — 243 243 9 — 234 0.98
Impairments and (gain)/loss on disposal of assets, net 4
— — 173 173 19 (23) 131 0.56
Litigation (recoveries)/charges, net — — (7) (7) (16) — 9 0.04
Non-GAAP $ 7,214 21 % $ 4,524 16 % $ 2,690 30 % $ 2,426 $ 430 $ (12) $ 1,984 33 % 17.7 % $ 8.35 36 %
Year-to-Date 2025
GAAP $ 5,966 8 % $ 3,898 5 % $ 1,847 N.M. $ 1,717 $ 391 $ (4) $ 1,322 N.M. 22.8 % $ 5.44 N.M.
Restructuring and employee severance — — 61 61 15 — 46 0.19
Amortization and other acquisition-related costs — — 331 331 81 (2) 248 1.02
Acquisition-related cash & share-based compensation costs — — 20 20 1 (4) 15 0.06
Impairments and (gain)/loss on disposal of assets, net — — (15) (15) (4) — (11) (0.04)
Litigation (recoveries)/charges, net — — (176) (176) (51) — (125) (0.51)
Non-GAAP $ 5,966 8 % $ 3,898 5 % $ 2,067 14 % $ 1,937 $ 431 $ (10) $ 1,495 6 % 22.3 % $ 6.16 8 %
1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.
2 Distribution, selling, general and administrative expenses.
3 Attributable to Cardinal Health, Inc.
4 For the nine months ended March 31, 2026, impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $184 million related to the Navista & ION reporting unit within the Pharma segment. For fiscal 2026, the estimated net tax benefit related to the impairments is $23 million and is included in the annual effective tax rate. The portion of the goodwill impairment charge attributable to noncontrolling interests is $23 million.
The sum of the components and certain computations may reflect rounding adjustments.
We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.
Schedule 6
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation - GAAP Cash Flow to Non-GAAP Adjusted Free Cash Flow
Third Quarter Year-to-Date
(in millions) 2026 2025 2026 2025
GAAP - Cash Flow Categories
Net cash provided by operating activities $ 1,823 $ 2,924 $ 3,482 $ 877
Net cash used in investing activities (181) (2,898) (2,303) (3,962)
Net cash provided by/(used in) financing activities (483) (514) (1,112) 1,277
Effect of exchange rates changes on cash and equivalents 1 4 (4) 1
Net increase/(decrease) in cash and equivalents $ 1,160 $ (484) $ 63 $ (1,807)
Non-GAAP Adjusted Free Cash Flow
Net cash provided by operating activities $ 1,823 $ 2,924 $ 3,482 $ 877
Repurchases of liability-classified Specialty Alliance Units 5 — 27 —
Additions to property and equipment (146) (126) (385) (315)
Payments related to matters included in litigation (recoveries)/charges, net 15 1 401 622
Non-GAAP Adjusted Free Cash Flow $ 1,697 $ 2,799 $ 3,525 $ 1,184
For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.
Schedule 7
Cardinal Health, Inc. and Subsidiaries
Distribution, Selling, General and Administrative ("SG&A") Expenses, excluding Acquisitions
Third Quarter Year-to-Date
Consolidated Consolidated
(in millions) 2026 2025 % Change (in millions) 2026 2025 % Change
SG&A expenses $ 1,542 $ 1,315 17 % SG&A expenses $ 4,507 $ 3,898 16 %
Less: Recent acquisitions1
216 80 N.M.
Less: Recent acquisitions1
569 97 N.M.
SG&A expenses, excluding recent acquisitions $ 1,326 $ 1,235 7 % SG&A expenses, excluding recent acquisitions $ 3,938 $ 3,801 4 %
1Recent acquisitions include Integrated Oncology Network (December 2024), GI Alliance (January 2025), Advanced Diabetes Supply Group (April 2025), Urology America (May 2025), and Solaris Health (November 2025).
Cardinal Health, Inc. and Subsidiaries
Use of Non-GAAP Measures
This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (“GAAP").
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.
•State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
•Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations.
•Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current, and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity, and size of acquisitions.
•Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs include fair value adjustments for liability-classified awards. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices.
•Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results.
•Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.
Non-GAAP adjusted free cash flow: We provide this non-GAAP financial measure as a supplemental metric to assist readers in assessing the effects of items and events on our cash flow on a year-over-year basis and in comparing our performance to that of our peer group companies. In calculating this non-GAAP metric, certain items are excluded from net cash provided by operating activities because they relate to significant and unusual or non-recurring events and are inherently unpredictable in timing and amount. We believe adjusted free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, debt repayments, dividend payments, share repurchases, strategic acquisitions, or other strategic uses of cash. A reconciliation of our GAAP financial results to Non-GAAP adjusted free cash flow is provided in Schedule 6 of the financial statement tables included with this release.
Forward Looking Non-GAAP Measures
In this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.
The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company’s fiscal 2026 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company’s EPS from $1.79 to $8.44, which includes a $6.97 charge related to the goodwill impairment charge for the GMPD segment in fiscal 2022.
Definitions
Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Interest and Other, net: other (income)/expense, net plus interest expense, net.
Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses).
Segment Profit margin: segment profit divided by segment revenue.
Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits).
Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessment related to prior fiscal years and shareholder cooperation agreement costs.
Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.
Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.
Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, divided by (earnings before income taxes adjusted for the items above).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.
Non-GAAP adjusted free cash flow: net cash provided by operating activities plus repurchases of liability-classified Specialty Alliance Units, less payments related to additions to property and equipment, excluding settlement payments and receipts related to matters included in litigation (recoveries)/charges, net, as defined above, or other significant and unusual or non-recurring cash payments or receipts.
GRAPHIC
GRAPHIC
Filename: essentialtocarea55.jpg · Sequence: 6
Binary file (9192 bytes)
Download essentialtocarea55.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover Page
Apr. 30, 2026
Cover [Abstract]
Document Type
8-K
Document Period End Date
Apr. 30, 2026
Entity Registrant Name
Cardinal Health, Inc.
Entity Incorporation, State or Country Code
OH
Entity File Number
1-11373
Entity Tax Identification Number
31-0958666
Entity Address, Address Line One
7000 Cardinal Place
Entity Address, City or Town
Dublin
Entity Address, State or Province
OH
Entity Address, Postal Zip Code
43017
City Area Code
614
Local Phone Number
757-5000
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common shares (without par value)
Trading Symbol
CAH
Security Exchange Name
NYSE
Entity Emerging Growth Company
false
Entity Central Index Key
0000721371
Amendment Flag
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration